Harvard Business Review

MAY 2, 2011

As multinational corporations pursue opportunities in emerging markets, they're bound to stumble if they overlook the developed economies, and vice versa. Nokia, for example, commanded market shares of 40% in China and 56% in India by 2008. Nokia, for example, commanded market shares of 40% in China and 56% in India by 2008.

Globalization 14

Globalization Marketing Venture Capitalist Biotechnology 14

Harvard Business Review

SEPTEMBER 14, 2011

In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. Dr Reddy's plan is to leverage Chirotech's scientific capabilities to optimize drug development processes, thus lowering manufacturing costs and speeding time-to-market.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. Innovating the Innovation Process. The Valley of Death. The Era of Big Science.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. In 2011, 71% of HBS's new cases were written about foreign companies. America fosters risk-taking and innovation by entrepreneurs who become global leaders.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

MARCH 5, 2012

Thus, the decline of manufacturing is not completely a result of "natural" market forces. And one look at the trade deficit ($558 billion in 2011) clearly indicates we don't have as much as our foreign competitors to sell in return. By subsidizing other industries so generously, we have tilted the scales away from manufacturing.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. If you’re in the upper right quadrant — or in the top 10 most uncertain industries as shown in the Table — you require greater innovation management skills than industries in the other quadrants or in the bottom 10.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22